Untitled Document

In The News

           Product
       Description


Board Of Directors

ALPHAMIR helps destroy tumor cells and various microorganisms such as bacteria, viruses protozoa and fungi. This approach to combat disease is totally different from the common practice of using toxic antimicrobial agents; rather, it utilizes the basic science within the white blood cells, called "the respiratory burst." The respiratory burst is the process by which the body's immune system produces bio-oxidants to destroy abnormal cells and invading microorganisms.

ALPHAMIR emulates this process by producing oxidative metabolites which are anti-microbial, immuno-stimulatory and non-toxic. This approach reinforces the natural immune system in combating harmful agents and regulates the production of serotonin, prostaglandin and inflammatory interleukins. Treating AIDS/HIV Worldwide

This newly patented medicinal agent "TRIOXOLANE" was developed by Dr. Stephen Herman to address the worldwide threat of the HIV/AIDS epidemic as well as numerous other viral, bacteriological, fungal, protozoal and autoimmune diseases.

After fourteen years of research and clinical trials, Immune Technologies, Inc. is honored to announce the development of an extraordinary breakthrough medicinal agent. This patented agent is a 1, 2, 4-Trioxolane designated as "ALPHAMIR". ALPHAMIR is a high energy bio-oxidant that mimics and augments the natural production of bio-oxidants by the human immune system and white blood cells.

Alphamir is non-toxic and microorganisms cannot develop resistance! It is effective in a broad spectrum of applications including HIV, autoimmune disease, arthritis, viral disease, infections, burns and numerous dermatological conditions. Alphamir requires no monitoring or training and will be available for a small fraction of the cost of present treatments.

Multiple clinical trials have been completed and ALPHAMIR has been registered and approved for sale by the Ministry of Health of Kenya, Africa for use in HIV/AIDS and arthritis. This approval, May 24, 2001, is valid in twenty-eight African Countries.

Top of Page